Blood:频繁献血小板(成份血)可导致CD4+/CD8+T淋巴细胞减少

2018-11-17 qinqiyun MedSci原创

在美国,每年有超过100万例血小板采集术。在偶然发现两例献血小板的健康人的CD4+T淋巴细胞计数较低后,John M. Gansner等人开展研究调查单献血小板是否会引起淋巴细胞减少。研究人员对采用Trima Accel(通过白细胞排泄系统腔连续清除白细胞)进行采集血小板的献血者进行横向的单中心研究。研究人员根据既往1年内的血小板捐献次数(1-2次、3-19次或20-24次)招募了3组血小板捐献者

在美国,每年有超过100万例血小板采集术。在偶然发现两例献血小板的健康人的CD4+T淋巴细胞计数较低后,John M. Gansner等人开展研究调查单献血小板是否会引起淋巴细胞减少。

研究人员对采用Trima Accel(通过白细胞排泄系统腔连续清除白细胞)进行采集血小板的献血者进行横向的单中心研究。研究人员根据既往1年内的血小板捐献次数(1-2次、3-19次或20-24次)招募了3组血小板捐献者,各组均有20位。1-2次组、3-19次组和20-24次组中T淋巴细胞计数低于200细胞/uL的人数分别为0人、2人和6人(p=0.019);CD8+T淋巴细胞计数较低的分别有0人、4人和11人(p<0.001)。各组白细胞排出系统腔的淋巴细胞提取效率均在15-20%之间。

免疫表型分析显示,各组的幼稚CD4+T淋巴细胞和Th17的百分比降低,CD4+和CD8+效应记忆细胞、Th1和Treg的百分比增加,而幼稚CD8+和Th2的百分比较稳定。

T细胞受体库分析显示所有组的克隆多样性相似。捐献者筛选问卷提示捐献者健康,每次捐献时都对包括HIV在内的多种病原体呈阴性反应。

对于捐献血小板的健康人,经常经白细胞排泄系统腔来采集血小板与其CD4+和CD8+T淋巴细胞减少有关。而CD4+和CD8+T淋巴细胞是人体重要的免疫细胞。其机制可能是在血小板分离的过程中反复提取淋巴细胞而导致其破坏减少。但这些血细胞减少似乎对人体无害,应进一步深入研究。


原始出处:

John M. Gansner,et al.Plateletpheresis-associated lymphopenia in frequent platelet donors. Blood  2018  :blood-2018-09-873125;  doi: https://doi.org/10.1182/blood-2018-09-873125

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1784056, encodeId=21b61e84056af, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Jul 02 04:25:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652593, encodeId=3060165259329, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Wed Jun 26 12:25:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864246, encodeId=ebc41864246d6, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Dec 29 03:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302206, encodeId=f1de130220692, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602906, encodeId=b7b71602906fb, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605391, encodeId=4f06160539189, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
    2019-07-02 gds2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1784056, encodeId=21b61e84056af, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Jul 02 04:25:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652593, encodeId=3060165259329, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Wed Jun 26 12:25:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864246, encodeId=ebc41864246d6, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Dec 29 03:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302206, encodeId=f1de130220692, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602906, encodeId=b7b71602906fb, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605391, encodeId=4f06160539189, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
    2019-06-26 xuyu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1784056, encodeId=21b61e84056af, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Jul 02 04:25:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652593, encodeId=3060165259329, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Wed Jun 26 12:25:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864246, encodeId=ebc41864246d6, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Dec 29 03:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302206, encodeId=f1de130220692, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602906, encodeId=b7b71602906fb, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605391, encodeId=4f06160539189, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
    2018-12-29 qidongfanjian
  4. [GetPortalCommentsPageByObjectIdResponse(id=1784056, encodeId=21b61e84056af, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Jul 02 04:25:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652593, encodeId=3060165259329, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Wed Jun 26 12:25:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864246, encodeId=ebc41864246d6, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Dec 29 03:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302206, encodeId=f1de130220692, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602906, encodeId=b7b71602906fb, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605391, encodeId=4f06160539189, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1784056, encodeId=21b61e84056af, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Jul 02 04:25:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652593, encodeId=3060165259329, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Wed Jun 26 12:25:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864246, encodeId=ebc41864246d6, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Dec 29 03:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302206, encodeId=f1de130220692, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602906, encodeId=b7b71602906fb, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605391, encodeId=4f06160539189, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1784056, encodeId=21b61e84056af, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Jul 02 04:25:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652593, encodeId=3060165259329, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Wed Jun 26 12:25:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864246, encodeId=ebc41864246d6, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Dec 29 03:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302206, encodeId=f1de130220692, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602906, encodeId=b7b71602906fb, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605391, encodeId=4f06160539189, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Mon Nov 19 11:25:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]

相关资讯

Circulation:过敏毒素受体C3aR参与调节血小板功能和动脉血栓形成原始出处:

血小板在血管系统中具有独特的功能,既是血栓形成的主要介质,对恢复组织完整性至关重要,又在血管炎症环境下发挥重要作用。补体系统是抵御微生物入侵的第一道防线,是炎症的重要介质。虽然补体和凝血系统之间的液相交叉很受重视,但其相互作用的病理生理意义尚不明确。研究人员采用流式细胞术分析了501位冠状动脉疾病患者血小板上激活的糖蛋白IIb/IIIa和过敏毒素受体C3aR共表达的情况;采用qPCR、免疫荧光、W

血小板相差大,该信谁?

血常规是每个检验科都必备的一个检验项目,其重要性不言而喻。在一些比较中大型医院的检验科往往会备有两台或两台以上的血细胞分析仪。多台血球仪的好处就是:当一台血球仪出现故障,可在另外一台血球仪上使用;做大批量体检时,也可节约很多时间。同时,也会暴露出一个致命的弱点:如果两台血球仪的结果之间存在较大差异怎么办?

Blood:VWF与血小板整合素结合的C4结构域的结构和动力学解析

血管假性血友病因子(VWF)是调控止血的关键因子,可促进招募血小板聚集到血管损伤处。由6个C端结构域形成二聚体C末端VWF阀杆。当剪切力激活时,阀杆变成开放性构象,允许VWF黏附到血小板和血管壁。要解析其潜在分子机制和疾病相关突变所导致的功能紊乱,明确C端结构域的结构和动力学首当其冲。研究人员发现VWF C4结构域的解结构可结合血小板整合素,对VWF功能至关重要。在该结构域中,我们发现了五个子结构

JAHA:地高辛通过影响血小板激活水平影响房颤患者预后

地高辛的使用与房颤患者不良心血管事件的发生相关,本研究提出假设,地高辛可以通过血小板的激活影响心血管风险。本研究是房颤抗凝患者前瞻性研究的事后分析,将患者分成地高辛使用组(n=132)和非地高辛使用组(n=388),并对其测定了血小板活化标志物血栓烷B2(TxB2)的尿排泄量和血清地高辛浓度(SDC)。本研究也同时进行了体外实验,将对照和房颤患者的血小板体外培养,并用标准剂量的地高辛进行孵育(0.

JAHA:英国研究称:心衰患者第二大死因是感染

据《美国心脏协会杂志》发表的一项研究,脓毒症是左心室射血分数降低心力衰竭患者死亡的主要原因。

Blood:TLT-1是ALI/ARDS的独立的预后标志物,可减轻急性肺损伤

每年超过20万人罹患急性肺损伤(ALI)和急性呼吸窘迫综合征(ARDS),死亡率高达40%。虽然血小板也参与ALI/ARDS进展,但其确切作用尚不明确。研究人员在血小板上发现了在髓细胞中表达的触发受体(TREM)样转录本(TLT)-1,可结合纤维蛋白原,介导血块形成。因而研究人员推测血小板通过TLT-1主导ALI/ARDS的进展。为证明上述推测,研究人员回顾性检测ARDSNET临床试验样本的血浆s